Floatz logo

Eniluracil

Neoplasms

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

928 Active assets in the Neoplasms cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB
LIDOCAINE
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

Eniluracil is also rated in:

rectal carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
rectum adenocarcinomaDormant
B
Indicative ·
62 / 100
View asset →
colon adenocarcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →